Efficacy and safety of anlotinib plus EGFR-TKI for advanced non-small cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.

ABSTRACT:

Background

To systematically evaluate the efficacy and safety of anlotinib plus epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR mutations.

Methods

This meta-analysis was registered with PROSPERO (Registration number: CRD420251102861). Up to July 11, 2025, the databases of PubMed, EMBASE, Cochrane Library, ClinicalTrials.gov, China National Knowledge Infrastructure, Chinese Biomedical Literature, China Science and Technology Journal, and Wanfang were searched, and the randomized controlled clinical trials of anlotinib plus EGFR-TKI in the treatment of advanced EGFR-mutant NSCLC were included. Two investigators independently screened the literature, assessed the quality of the inclu

SUBMITTER: Li D 

PROVIDER: S-EPMC12582816 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature